Cudkowicz ME - Search Results

1

Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development.

Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, Chase M, Sherman AV, Yu H, Drake K, Andrews J, Shefner J, Chibnik LB, Vestrucci M, Cudkowicz ME; Healey ALS Platform Trial Study Group. Paganoni S, et al. Among authors: cudkowicz me. Ann Neurol. 2022 Feb;91(2):165-175. doi: 10.1002/ana.26285. Epub 2022 Jan 10. Ann Neurol. 2022. PMID: 34935174 Review.

2

An update on superoxide dismutase 1 in familial amyotrophic lateral sclerosis.

Cudkowicz ME, Brown RH Jr. Cudkowicz ME, et al. J Neurol Sci. 1996 Aug;139 Suppl:10-5. doi: 10.1016/0022-510x(96)00084-6. J Neurol Sci. 1996. PMID: 8899652 Review. No abstract available.

3

Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis.

Cudkowicz ME, McKenna-Yasek D, Sapp PE, Chin W, Geller B, Hayden DL, Schoenfeld DA, Hosler BA, Horvitz HR, Brown RH. Cudkowicz ME, et al. Ann Neurol. 1997 Feb;41(2):210-21. doi: 10.1002/ana.410410212. Ann Neurol. 1997. PMID: 9029070

4

Intrathecal administration of recombinant human superoxide dismutase 1 in amyotrophic lateral sclerosis: a preliminary safety and pharmacokinetic study.

Cudkowicz ME, Warren L, Francis JW, Lloyd KJ, Friedlander RM, Borges LF, Kassem N, Munsat TL, Brown RH Jr. Cudkowicz ME, et al. Neurology. 1997 Jul;49(1):213-22. doi: 10.1212/wnl.49.1.213. Neurology. 1997. PMID: 9222193 Clinical Trial.

5

Limited corticospinal tract involvement in amyotrophic lateral sclerosis subjects with the A4V mutation in the copper/zinc superoxide dismutase gene.

Cudkowicz ME, McKenna-Yasek D, Chen C, Hedley-Whyte ET, Brown RH Jr. Cudkowicz ME, et al. Ann Neurol. 1998 Jun;43(6):703-10. doi: 10.1002/ana.410430604. Ann Neurol. 1998. PMID: 9629839

6

Increased CSF F2-isoprostane concentration in probable AD.

Montine TJ, Beal MF, Cudkowicz ME, O'Donnell H, Margolin RA, McFarland L, Bachrach AF, Zackert WE, Roberts LJ, Morrow JD. Montine TJ, et al. Among authors: cudkowicz me. Neurology. 1999 Feb;52(3):562-5. doi: 10.1212/wnl.52.3.562. Neurology. 1999. PMID: 10025788

7

Administration of nitric oxide synthase inhibitors does not alter disease course of amyotrophic lateral sclerosis SOD1 mutant transgenic mice.

Upton-Rice MN, Cudkowicz ME, Mathew RK, Reif D, Brown RH Jr. Upton-Rice MN, et al. Among authors: cudkowicz me. Ann Neurol. 1999 Mar;45(3):413-4. doi: 10.1002/1531-8249(199903)45:3<413::aid-ana24>3.0.co;2-5. Ann Neurol. 1999. PMID: 10072062 No abstract available.

8

The pharmacokinetics and pharmaco-dynamics of Procysteine in amyotrophic lateral sclerosis.

Cudkowicz ME, Sexton PM, Ellis T, Hayden DL, Gwilt PR, Whalen J, Brown RH Jr. Cudkowicz ME, et al. Neurology. 1999 Apr 22;52(7):1492-4. doi: 10.1212/wnl.52.7.1492. Neurology. 1999. PMID: 10227642 Clinical Trial.

9

Basic fibroblast growth factor does not prolong survival in a transgenic model of familial amyotrophic lateral sclerosis.

Upton-Rice MN, Cudkowicz ME, Warren L, Mathew RK, Ren JM, Finklestein SP, Brown RH Jr. Upton-Rice MN, et al. Among authors: cudkowicz me. Ann Neurol. 1999 Dec;46(6):934. doi: 10.1002/1531-8249(199912)46:6<934::aid-ana21>3.0.co;2-0. Ann Neurol. 1999. PMID: 10589551 No abstract available.

10

Increased oxidative damage to DNA in ALS patients.

Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, Flint Beal M, Cudkowicz M. Bogdanov M, et al. Free Radic Biol Med. 2000 Oct 1;29(7):652-8. doi: 10.1016/s0891-5849(00)00349-x. Free Radic Biol Med. 2000. PMID: 11033417

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page